OCRELIZUMAB for Off label use: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 35 adverse event reports in the FDA FAERS database where OCRELIZUMAB was used for Off label use.
Most Reported Side Effects for OCRELIZUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Covid-19 | 11,454 | 20.4% | 322 | 2,256 |
| Fatigue | 5,704 | 10.2% | 20 | 1,174 |
| Urinary tract infection | 3,618 | 6.4% | 52 | 1,503 |
| Headache | 3,036 | 5.4% | 13 | 660 |
| Multiple sclerosis | 2,609 | 4.6% | 28 | 604 |
| Asthenia | 2,509 | 4.5% | 23 | 879 |
| Nasopharyngitis | 2,479 | 4.4% | 7 | 441 |
| Gait disturbance | 2,384 | 4.2% | 18 | 769 |
| Pneumonia | 2,333 | 4.2% | 132 | 1,254 |
| Pain | 2,327 | 4.1% | 11 | 623 |
| Multiple sclerosis relapse | 2,326 | 4.1% | 7 | 576 |
| Fall | 2,209 | 3.9% | 31 | 973 |
| Off label use | 2,198 | 3.9% | 44 | 629 |
| Infusion related reaction | 2,116 | 3.8% | 5 | 287 |
| Drug ineffective | 2,018 | 3.6% | 14 | 306 |
Other Indications for OCRELIZUMAB
Relapsing-remitting multiple sclerosis (15,658)
Multiple sclerosis (15,501)
Product used for unknown indication (10,715)
Relapsing multiple sclerosis (6,883)
Primary progressive multiple sclerosis (6,156)
Secondary progressive multiple sclerosis (1,273)
Progressive multiple sclerosis (400)
Multiple sclerosis relapse (373)
Progressive relapsing multiple sclerosis (123)
Neuromyelitis optica spectrum disorder (57)
Other Drugs Used for Off label use
LENALIDOMIDE (5,767)
ECULIZUMAB (3,550)
CERTOLIZUMAB PEGOL (2,256)
ABOBOTULINUMTOXINA (2,170)
LEVETIRACETAM (2,161)
APREMILAST (1,995)
PROPRANOLOL (1,576)
CETIRIZINE (1,416)
HUMAN IMMUNOGLOBULIN G (1,129)
THALIDOMIDE (1,033)